What do you think are the big questions to be answered next in your field? A big question in the field is the extent to which we can identify and understand the diversity of cell types within the central nervous system. Single-cell RNA-seq and the Human Cell Atlas are providing unprecedented detail on the diversity of cell types in developing and mature neural circuits. Indeed, an exciting advance of the past decade has been an appreciation that glial cells are also diversified. This helped emphasize the need for new stratified approaches to find out the relative capabilities of oligodendrocyte lineage cells in modulation of neural circuits and myelination; to determine whether astrocytes are homogeneous or regionally specialized to enhance the function of local circuits and, if so, how this diversity is programmed; and to investigate diverse origins and roles for microglia. Understanding the functional panoply of glia, which comprise over 90% of cells in human brain, would transform our baseline understanding of neurological function and disease.
To tackle your favorite research question, is there a tool that either needs to be developed or is currently available that could be implemented in a novel way? Rather than a tool, I think certain resources would greatly enhance our progress in understanding the conservation of mechanisms between experimental systems in neuroscience and the human brain. The Human Cell Atlas could provide useful datasets and multiplex imaging to describe neural cells and circuits in unprecedented detail to take observations to the mechanistic level. Tissue banks encompassing human brain development and diseases are critical for validation of candidate regulatory genes and pathways in situ; however, such cell and tissue resources are scarce. Alternatives, such as embryonic stem cell-(ESC) or induced pluripotent stem cell (iPSC)-derived cells, show promise but might fail to capture the full range of diversity, cell-cell interaction, and circuit activities in the intact tissue. In general, limited access to high-quality human brain samples limits many investigators from taking key steps in validation.
The Cell Symposium that you are speaking at this year covers talks from cell biology to cognition and from animal models to human neuroscience. How do you view the level of crosstalk between these disciplines, and how can they profit/ learn from each other? My previous answer addresses this issue. The ability to share results from different systems is essential for rapid translation of insights from animal models to the human brain. This has traditionally
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University of Cambridge encouraged crosstalk between basic scientists and clinicians. However, human behavior and cognition are not faithfully captured in many animal systems, suggesting that genome and population biology studies to assess mental health and integration of other approaches using artificial intelligence might extend our mechanistic understanding of human neurological function and the impact of disease/injury. Do you have a favorite anecdote from doing science that you'd like to share (perhaps a key discovery moment)? A great example of team science involved the cloning and characterization of vertebrate Hedgehog pathway genes by the laboratories of Andrew McMahon, Clifford Tabin, and Philip Ingham, supported by funding from the Human Frontier Science Project. Through intensive sharing of raw data between these groups, there was rapid progress identifying orthologs of Drosophila hedgehog. Clones for Sonic hedgehog, Indian hedgehog, and Desert hedgehog in mouse, chick, and zebrafish took a matter of months, resulting in three co-published papers defining a major novel developmental pathway. As a postdoc in the lab, I was inspired by the model and how three labs could collaborate to achieve rapid success.
Who were your key early influences?
My early influences in the lab were Kathryn Calame, Sir Tim Hunt, and Andy McMahon. All expected a high degree of intellectual rigor, doing experiments oneself rather than trusting the results of others, yet being generous with reagents from the lab to facilitate others' progress.
What's your favorite experiment? I was fascinated by reports of conservation of gene function during evolution from yeast to human from Sir Paul Nurse's laboratory, which convinced me that fundamental experimental systems such as Drosophila would shed light on mammalian brain development.
What has been the highlight of your career? Investigations in my laboratory in collaboration with Chuck Stiles identified bHLH proteins Olig1 and Olig2, which were the first transcription factors required for patterning and specification of a glial lineage, oligodendrocytes. Further research has shown that glial diversity is determined by a segmental patterning mechanism similar to neurons.
What do you do when you're not in the lab? I enjoy running the trails in Marin County and Cambridgeshire.
Which aspect of science, your field or in general, do you wish the general public knew more about? There are many human neurological disorders with genetic causes or influences. Especially in children, the use of whole-genome sequencing will greatly enhance our ability to detect genetic causes of neurological disorders, and it will also point the way to precision therapies. For example, identifying patients with genetic specificity will help us to find existing drugs (repurposing) that work better for their needs. Babies with seizures and mutation of the potassium channel, KCNQ2, respond better to carbamazepine versus other anti-epileptic drugs. Moreover, we are making great strides in gene and regenerative therapy approaches. This promises a new generation of therapeutic options for rare neurogenetic disease, as well as more common neurodegenerative diseases in children and adults.
What do you think are the biggest problems/challenges science as a whole is facing today? I am afraid that significant challenges facing science are at the government level. Just at a time when we could make rapid progress in biomedical sciences through enhanced investment in basic and clinical research, the budget of the NIH seems under threat and less vigorously supported by politicians. This reflects, in part, a skepticism from some factions about scientific principles and findings, which is a concern because scientific literacy is an important societal priority. There is an opportunity to develop novel big data international collaborations that have traditionally been employed in the fields of engineering and astrophysics, but these seem under threat, as well. The Brexit vote in the UK will have an uncertain impact on the future of UK European scientific collaborations.
What is your view on big datagathering collaborations as opposed to hypothesis-driven research by small groups? Big data approaches are a critical ingredient to make progress in biological and biomedical science. We are generating unprecedented complexity in datasets for biological systems and cancer, but in the future this will extend to human development and disease as we begin to integrate whole-genome, epigenome, and other biomarker profiles with human patient health outcomes, and even educational, social, and behavioral outcomes and mental health. But at the end of the day, hypothesis-generating approaches must be tested and this means retaining core strengths in basic science and experimental models. Smaller groups with focus have time and again made great discoveries that were not planned and could not have been anticipated, indicating that flexibility and serendipitous routes must be protected.
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